Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C.
NBIX Key Statistics
NBIX News
Neurocrine Biosciences ( ) First Quarter 2024 Results Key Financial Results Revenue: US$515.3m (up 23% from 1Q 2023). Net income: US$43.4m (up from US$76.6m...
Neurocrine Biosciences Inc showcases robust revenue growth and operational efficiency. Strategic collaborations and late-stage clinical programs position NBIX...
Participants Eiry Wyn Roberts; Chief Medical Officer; Neurocrine Biosciences, Inc. Eric S. Benevich; Chief Commercial Officer; Neurocrine Biosciences, Inc. J...
Analyst ratings
71%
of 28 ratingsMore NBIX News
Loading... Loading... In the latest quarter, 11 analysts provided ratings for Neurocrine Biosciences NBIX, showcasing a mix of bullish and bearish perspectives...
Neurocrine (NASDAQ:NBIX) released a Q1 earnings report that beat Street revenue estimates, the day after announcing the FDA had approved an easier-to-swallow fo...
Neurocrine Biosciences Neurocrine Biosciences NBIX $ 140.11 $2.57 1.87% 19% IBD Stock Analysis Stock has flat base with 148.37 buy point 145 is early entry Re...
The US Food and Drug Administration (FDA) has approved an alternative formulation for Neurocrine Biosciences’ Huntington’s disease therapy, Ingrezza (valbenazin...
Neurocrine Biosciences (NBIX) reported $515.3 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 22.6%. EPS of $0.42...
Neurocrine Biosciences (NBIX) stock popped early Wednesday after the top-notch biotech company reported adjusted earnings of $1.20 per share on $515.3 million i...
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $1.04 per share. This compares to los...
